Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metabolic Dysfunction-Associated Steatohepatitis (MASH): early-phase trial registry
4 of 6 indexed Metabolic Dysfunction-Associated Steatohepatitis (MASH) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 4 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Metabolic Dysfunction-Associated Steatohepatitis (MASH): 6 US clinical trials tracked, 4 recruiting.
Metabolic Dysfunction-Associated Steatohepatitis (MASH) is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Corcept Therapeutics, running 2 of these trials.
Enrollment posture brief
Registry condition metabolic-dysfunction-associated-steatohepatitis-mash
OPEN 4 | RECR 67% | LATE 2 | EARLY 4 | RANK #2866 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adenocarcinoma of Lung (67% recruiting · 6 trials)
Metabolic Dysfunction-Associated Steatohepatitis (MASH) lists 4 open slots (67% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metabolic Dysfunction-Associated Steatohepatitis (MASH) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metabolic Dysfunction-Associated Steatohepatitis (MASH) is recruiting above its size-band peers.
4 of 6 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metabolic Dysfunction-Associated Steatohepatitis (MASH) research.
Corcept Therapeutics accounts for 2 of 6 trials (33.3%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical Metabolic Dysfunction-Associated Steatohepatitis (MASH) enrolment sits around 175 participants.
Median target enrolment is 175 among the 6 trials that report a genuine target (sentinel values excluded). 2 of those (33.3%) plan for fewer than 100 participants.
-
Metabolic Dysfunction-Associated Steatohepatitis (MASH) research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Boehringer Ingelheim
NCT06632444
Fibrosis Lessens After Metabolic Surgery
Ali Aminian
NCT06374875
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Regeneron Pharmaceuticals
NCT05519475
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Corcept Therapeutics
NCT06947304
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Eli Lilly and Company
NCT05395481
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
Corcept Therapeutics
NCT06108219
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metabolic Dysfunction-Associated Steatohepatitis (MASH) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metabolic Dysfunction-Associated Steatohepatitis (MASH) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metabolic Dysfunction-Associated Steatohepatitis (MASH) page
6 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Metabolic Dysfunction-Associated Steatohepatitis (MASH) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Corcept Therapeutics sponsors the most Metabolic Dysfunction-Associated Steatohepatitis (MASH) trials on record, review their full trial history before evaluating a specific study. See Corcept Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metabolic Dysfunction-Associated Steatohepatitis (MASH) condition card totals 6 registered trials; most-linked intervention Placebo; top US site state Arizona. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.